Brigatinib, a leading second-generation ALK tyrosine kinase inhibitor, is a critical targeted therapy for treating ALK-positive non-small cell lung cancer (NSCLC). Widely recognized under the brand name ALUNBRIG, this high-value pharmaceutical compound is in constant global demand across clinical research, pharmaceutical manufacturing, hospital procurement, and international drug distribution sectors. Understanding the Brigatinib global buyers list enables API suppliers, pharmaceutical manufacturers, and wholesale distributors to identify legitimate, high-intent procurement partners, streamline cross-border trade, and align production capacity with global market demand. Unlike generic pharmaceutical products, Brigatinib features strict quality certification standards, regulatory compliance requirements, and niche market demand. Its global buyer base is highly specialized, consisting of certified pharmaceutical enterprises, institutional…